184 related articles for article (PubMed ID: 37593676)
21. Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single-center retrospective study in Japan.
Otsuka M; Sugihara S; Mori S; Hamada K; Sasaki Y; Yoshikawa S; Kiyohara Y
J Dermatol; 2020 Apr; 47(4):356-362. PubMed ID: 31984569
[TBL] [Abstract][Full Text] [Related]
22. Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.
van Eijs MJM; Verheijden RJ; van der Wees SA; Nierkens S; van Lindert ASR; Suijkerbuijk KPM; van Wijk F;
Cancer Immunol Immunother; 2023 Dec; 72(12):4049-4064. PubMed ID: 37794264
[TBL] [Abstract][Full Text] [Related]
23. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
Front Immunol; 2022; 13():779691. PubMed ID: 35558065
[TBL] [Abstract][Full Text] [Related]
24. Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect.
Boegeholz J; Brueggen CS; Pauli C; Dimitriou F; Haralambieva E; Dummer R; Manz MG; Widmer CC
BMC Cancer; 2020 Apr; 20(1):300. PubMed ID: 32290812
[TBL] [Abstract][Full Text] [Related]
25. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.
Hribernik N; Huff DT; Studen A; Zevnik K; Klaneček Ž; Emamekhoo H; Škalic K; Jeraj R; Reberšek M
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1857-1869. PubMed ID: 34958422
[TBL] [Abstract][Full Text] [Related]
26. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
Ye W; Olsson-Brown A; Watson RA; Cheung VTF; Morgan RD; Nassiri I; Cooper R; Taylor CA; Akbani U; Brain O; Matin RN; Coupe N; Middleton MR; Coles M; Sacco JJ; Payne MJ; Fairfax BP
Br J Cancer; 2021 May; 124(10):1661-1669. PubMed ID: 33723392
[TBL] [Abstract][Full Text] [Related]
27. Predictors for the development of neurological immune-related adverse events of immune checkpoint inhibitors and impact on mortality.
Yan C; Huang M; Swetlik C; Toljan K; Mahadeen AZ; Bena J; Kunchok A; Funchain P; McGinley M
Eur J Neurol; 2023 Oct; 30(10):3221-3227. PubMed ID: 37350150
[TBL] [Abstract][Full Text] [Related]
28. Assessment of hospitalization rates for immune-related adverse events with immune checkpoint inhibitors.
Nice L; Bycroft R; Wu X; Rai SN; Figg L; Bhandari S; Burd M
J Oncol Pharm Pract; 2021 Oct; 27(7):1736-1742. PubMed ID: 33100180
[TBL] [Abstract][Full Text] [Related]
29. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
[TBL] [Abstract][Full Text] [Related]
30. Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy.
Bai X; Hu J; Betof Warner A; Quach HT; Cann CG; Zhang MZ; Si L; Tang B; Cui C; Yang X; Wei X; Pallan L; Harvey C; Manos MP; Ouyang O; Kim MS; Kasumova G; Cohen JV; Lawrence DP; Freedman C; Fadden RM; Rubin KM; Sharova T; Frederick DT; Flaherty KT; Rahma OE; Long GV; Menzies AM; Guo J; Shoushtari AN; Johnson DB; Sullivan RJ; Boland GM
Clin Cancer Res; 2021 Nov; 27(21):5993-6000. PubMed ID: 34376536
[TBL] [Abstract][Full Text] [Related]
31. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
32. Immune signatures of checkpoint inhibitor-induced autoimmunity-A focus on neurotoxicity.
Müller-Jensen L; Schulz AR; Mei HE; Mohr R; Ulrich C; Knape P; Frost N; Frischbutter S; Kunkel D; Schinke C; Ginesta Roque L; Maierhof SK; Nickel FT; Heinzerling L; Endres M; Boehmerle W; Huehnchen P; Knauss S
Neuro Oncol; 2024 Feb; 26(2):279-294. PubMed ID: 37823709
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
[TBL] [Abstract][Full Text] [Related]
34. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
[TBL] [Abstract][Full Text] [Related]
35. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.
Tobin RP; Jordan KR; Robinson WA; Davis D; Borges VF; Gonzalez R; Lewis KD; McCarter MD
Int Immunopharmacol; 2018 Oct; 63():282-291. PubMed ID: 30121453
[TBL] [Abstract][Full Text] [Related]
36. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.
Kim ST; Chu Y; Misoi M; Suarez-Almazor ME; Tayar JH; Lu H; Buni M; Kramer J; Rodriguez E; Hussain Z; Neelapu SS; Wang J; Shah AY; Tannir NM; Campbell MT; Gibbons DL; Cascone T; Lu C; Blumenschein GR; Altan M; Lim B; Valero V; Loghin ME; Tu J; Westin SN; Naing A; Garcia-Manero G; Abdel-Wahab N; Tawbi HA; Hwu P; Oliva ICG; Davies MA; Patel SP; Zou J; Futreal A; Diab A; Wang L; Nurieva R
Nat Commun; 2022 Apr; 13(1):1970. PubMed ID: 35413951
[TBL] [Abstract][Full Text] [Related]
37. Safety of sequential immune checkpoint inhibitors after prior immune therapy.
Awidi M; Connell B; Johnson D; Craven I; Ranjit R; Gil B; Dal'Bo N; Maher L; Daves SR; McDonald S; Gunturu KS
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2375-2382. PubMed ID: 35727369
[TBL] [Abstract][Full Text] [Related]
38. CD4 T cells and toxicity from immune checkpoint blockade.
Earland N; Zhang W; Usmani A; Nene A; Bacchiocchi A; Chen DY; Sznol M; Halaban R; Chaudhuri AA; Newman AM
Immunol Rev; 2023 Sep; 318(1):96-109. PubMed ID: 37491734
[TBL] [Abstract][Full Text] [Related]
39. MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade.
Mukherjee N; Katsnelson E; Brunetti TM; Michel K; Couts KL; Lambert KA; Robinson WA; McCarter MD; Norris DA; Tobin RP; Shellman YG
Cell Death Dis; 2024 Mar; 15(3):198. PubMed ID: 38459020
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitors for the treatment of melanoma.
Sabbatino F; Liguori L; Pepe S; Ferrone S
Expert Opin Biol Ther; 2022 May; 22(5):563-576. PubMed ID: 35130816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
